Namandjé N. Bumpus Principal Deputy Commissioner at U.S. Food And Drug Administration (fda) | Official website
Namandjé N. Bumpus Principal Deputy Commissioner at U.S. Food And Drug Administration (fda) | Official website
This is a 100% increase over the number of companies cited in the previous year.
The citations in the county include:
- Your extralabel use of an approved human or animal drug caused a residue above an established safe level, safe concentration, or tolerance.
- You did not keep, maintain complete and retain treatment records.
- Your written SE prevention plan lacks appropriate SE prevention measures.
Both companies cited should take voluntary actions to correct their managing operations.
The FDA routinely inspects facilities across the nation to determine if the workplace and their products are compliant with FDA-regulated laws and regulations implemented to improve overall public health. Inspection results are then disclosed publicly.
According to its website, the FDA is a government agency that is primarily responsible for monitoring the production and distribution of human and animal drugs, biological products, medical supplies and tobacco products for safety quality.
| Company Name | Area of Business | Inspection Date | Issue Cited |
|---|---|---|---|
| Budden, Randy | Veterinary | 03/11/2024 | ELDU - producer causes Illegal drug residue |
| Budden, Randy | Veterinary | 03/11/2024 | Record keeping |
| Enos Eggs | Food and Cosmetics | 09/16/2024 | Written SE plan lacks required elements |
| Enos Eggs | Food and Cosmetics | 09/16/2024 | Plan appropriate to layout |
Alerts Sign-up